共 14 条
[1]
Second generation SSRIs:human monoamine transporter binding profile of escitalopramand R-fluoxetine. Owens MJ,Knight DL,Nemeroff CB. Biological Psychiatry . 2001
[2]
Evaluation of the cost effec-tiveness of escitalopramversus venlafaxine XRin major depressive dis-order. Fernandez JL,Montgomery S,Francois C. Pharmacoeconomics . 2005
[3]
Efficacy comparison of escitalopramand citalopraminthetreatment of major depressive disorder:pooled analysis of placebo-controlledtrials. Gorman JM,Korotzer A,Su G. CNS Spectrums . 2002
[4]
Adouble-blind comparison of esci-talopramand venlafaxine extendedrelease inthe treatment of major de-pressive disorder. Bielski RJ,Ventura D,Chang CC. Journal of Clinical Psychiatry . 2004
[5]
Definition and epidemiology of treatment resis-tant depression. Fava M,Davidson KG. Psychiatric Clinics of North America . 1996
[6]
Escitalopram:a reviewof its use in the manage-ment of major depressive disorder. Murdoch D,KeamSJ. Drugs . 2005
[7]
Arandomized study compar-ing escitalopramwith venlafaxine XRin primary care patients with ma-jor depressive disorder. Montgomery SA,HuusomAKT,Bothmer J. Neuropsychobiology . 2004
[8]
Affinity modulation of[3H]imipramine[3H]paroxetine and[3H]citaloprambindingto the5-HT transporter frombrain and platelets. Plenge P,Mellerup ET,Laursen H. European Journal of Pharmacology . 1991
[9]
R-citalopramattenuates anxiolytic effects of escitalopramin arat ultrasonic vocalization model. Sanchez C. European Journal of Pharmacology . 2003
[10]
The Concept of Remission:validity andlimitations. Thase ME. Journal of Clinical Psychiatry . 2006